🚨🔥OncoAlert Hot Off The Press U.S. FDA approves #Taletrectinib for locally advanced or metastatic #ROS1+ non-small cell #LungCancer. Approval based on #TRUST I & II Trials. ✅#ORR: 85-90% for treatment-naive pts. 52-62% or TKI-pretreated pts. 👇🏻 fda.gov/drugs/resource…

📺BREAKING VIDEO Overview: 🚨FDA Approves TALETRECTINIB 🫁NSCLC ROS1+ 🎉 TRUST-I Trial: 90% ORR 📊72% DOR ≥12mo naive!⏲️ 📰 Article With References: oncologytube.com/fda-approves-t… #CancerResearch #LungCancer #ASCO25 Top Biomedical Science OncoAlert gilberto lopes Narjust Florez, MD, FASCO 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏

It was exactly 30 years ago today that i left from post-Iron Curtain Eastern Europe for JFK airport and the American Dream with a suitcase + $500 of our family fortune (vanished in 1 day in a nasty US scheme called housing deposit for below studio) AIDS crisis (stuck myself 2nd

IMforte: Phase 3 trial The Lancet ➡️Pts w/ ES-SCLC were randomized to receive Lurbinectedin +atezo vs Atezo after 4 cycles of chemo-atezo ➡️↑ in PFS (5.4 vs 2.1 mo) & OS (13.2 vs. 10.6 mo) with atezo + Lurbinectedin OncoAlert The Cancer News #LCSM thelancet.com/journals/lance…

Dipesh Uprety Highlighted Phase 3 IMforte trial on First-line Maintenance Therapy With Lurbinectedin Plus Atezolizumab in SCLC Dipesh Uprety MD FACP oncodaily.com/insight/lurbin… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedEd #MedNews #Lurbinectedin #Atezolizumab #SCLC

🚨🔥OncoAlert Hot Off The Press #BigNews U.S. FDA grants #accelerated approval for #Datopotamab for #patients: ✅With locally advanced or metastatic #EGFRm non-small cell #LungCancer. & ✅ Have received prior #EGFR targeted therapy & prior chemotherapy. 💥Approval is based

📢 We're excited to welcome you today at 5:30 PM CEST for a deep dive into IO in #NSCLC. Solange Peters, Patrick Forde & Jordi Remon will debate neoadjuvant vs. perioperative IO, explore dual IO strategies, share practical insights, and discuss key data from #ASCO25. #LCSM

Looking forward to an outstanding virtual summit on a hot topic - designing the newest clinical trials in earlier stage cancers that can be removed by surgery. Truly world leading panel to discuss key areas in this rapidly changing field. Join us for free online! Society for Immunotherapy of Cancer #lcsm

1/2🔥🚨Hot off the press Just published on #ASCODailyNews ASCO 📝Editorial Article by our team Mayo Clinic Comprehensive Cancer Center on: ✅#MARIPOSA trial & latest developments in #Treatment of #EGFR+ non-small cell #LungCancer (#NSCLC). Reema Tawfiq, MD Vamsi Velcheti, MD MBA FASCO 👇🏻 dailynews.ascopubs.org/do/butterfly-e…

🔥🚨OncoAlert Hot Off The Press U.S. FDA approves: ✅ #Sunvozertinib For: 🔘Advanced non-small cell #LungCancer (#NSCLC) with: 🎯#EGFR #Exon20 insertion mutations, and disease progression on or after chemotherapy. ⭐️#ORR 46% and #DOR 11.1 months 👇🏻 fda.gov/drugs/resource…

💡Starting out in thoracic oncology? The IASLC Communications Committee proudly brings you: ‘50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic’ A whistlestop tour of key advances, distilled by global leaders JTO & JTO CRR OncoAlert #LCSM jto.org/article/S1556-…

Excited to share our IASLC paper: 🧭 “50 Years of Progress in #NSCLC” JTO & JTO CRR A review of breakthroughs in #LungCancer—from chemo to targeted therapy to #immunotherapy ! 🔗 bit.ly/44wRj6w OncoAlert LungCancerRx 🫁💊 Oncology Brothers Hem-Onc Fellows Network UAB O'Neal Comprehensive Cancer Center

Be sure to attend #DCLung25 - Saturday, October 4th in Washington DC: a one-day IASLC endorsed lung cancer conference with experts like Dr. Sandip Patel Sandip Patel MD FASCO, who will discuss immunotherapy combinations for NSCLC. Register today! medstarhealth.org/dclung25

Hot off the press a 🚨 Must-read review on optimizing treatment for #LungCancer with activating EGFR mutations , a true game changer in targeted therapy. TKIs have transformed outcomes, but the journey continues. 👉 acsjournals.onlinelibrary.wiley.com/doi/full/10.33… thanks to all the co-authors, great team

🔥🚨HOT OFF THE PRESS Published Journal of Clinical Oncology TWO ASCO Living #Guideline updates Version 2025.1 by great experts on: Therapy for Stage IV Non-Small Cell #LungCancer: 1) WITHOUT Driver Alterations 👉 brnw.ch/21wUfz5 2) WITH Driver Alterations 👉 brnw.ch/21wUekt

You need some data as to how to use dato? Below guide offers a practical way to use Datroway in your clinic! ☑️mucositis ☑️pneumonitis ☑️ocular tox Now that Dato-dxd is approved for both breast and EGFR-mutated NSCLC indications, implementation of best practices is key! 👀

⏰ For the incoming Hem-Onc Fellows Network Great summary of progress in lung cancer from the IASLC Comm Committee: 50 years of Progress in Non-Small Cell Lung Cancer: A New Fellow’s Guide in the Clinic - Journal of Thoracic Oncology jto.org/article/S1556-… IASLC #lcsm Jarushka Naidoo

🔥🚨Hot Off The Press. U.S. FDA just approved: ⭐️#Zongertinib (#Oral, irreversible, HER2 #TKI) for: ✅#Patients with previously treated, advanced #HER2-mutant non-small- cell #LungCancer (#NSCLC). Approval based on results of #BeamionLung1 Trial. 👇🏻 fda.gov/drugs/resource…

As early-career oncologist, starting my second year of Faculty, I quickly learned that clinical skills are only part of the job. Here in this article, we reflect about the things that fellowship didn’tcover, and how to survive and thrive! Ibrahim Azar, MD connection.asco.org/do/eight-aspec…

Excited to announce my promotion to Associate Professor #LCSM 😊